Share
Hello All,
We urgently need funds for treatment of Prerna Katiyar who has been diagnosed with Adenocarcinoma of the Lung. She is a mother of two kids -- nine-year-old daughter and three-year-old son.
We urgently need funds for treatment of Prerna Katiyar who has been diagnosed with Adenocarcinoma of the Lung. She is a mother of two kids -- nine-year-old daughter and three-year-old son.
She is a Journalist by profession and currently working as Senior Assistant Editor with a business newspaper of the country. Over the years she has been covering topics of national interest as well as those affecting disadvantaged groups. A link to her articles is given below:
https://m.economictimes.com/etreporter/author-prerna-katiyar-479240278.cms
She has Stage IV Non Small Cell Lung Cancer (NSCLC). Unfortunately, the cancerous cells are EGFR positive with a rare Exon-20 insertion mutation.
IN BRIEF
Name: Prerna Katiyar
Age: 40 years
Location: New Delhi
Hospital where Cancer was diagnosed: Rajiv Gandhi Cancer Institute and Research Centre
Working at: The Economic Times
Disease: Non Small Cell Lung Cancer with EGFR, Exon-20 Insertion Mutation
Drug Required: Rybrevant / Amivantamab
Amount to be Raised: Rs. 2,04,00,000 ($ 2,55,000)
As of now there is a single targeted therapy drug called Amivantamab of Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, which has been approved by FDA for Exon-20 mutations. The approval has been granted only recently in May 2021. The trade name of the drug is now Rybrevant.
https://www.pharmaceutical-technology.com/news/fda-janssen-rybrevant/
Amivantamab can be used to treat advanced NSCLC when the cells have an exon 20
mutation. This drug is given as an infusion
into a vein (IV).
https://www.cancer.org/content/dam/CRC/PDF/Public/8706.00.pdf (Pg. 22)
It has shown promise compared to other alternative Exon-20 specific targeted therapies, all of which are currently at clinical trial stage only.
https://www.clinicaltrialsarena.com/comment/janssens-amivantamab-has-competitive-edge-over-spectrums-and-takedas-exon-20-mutation-directed-tkis-in-nsclc/
As of now, the drug is not available in India and it is also not available for import. The situation is expected to remain the same for the coming few months. Hence, presently the only way to commercially access the drug is to get it in the US.
Since the cancer cells have already spread to her right leg, we want to start her treatment right away wherever the drug is available and come back to India as soon as the drug becomes available in India.
Three vials of the drug are required to be administered every week for the first four weeks, and subsequently infusion of three vials would be required once every two weeks. This drug would be administered along with Chemotherapy.
Being a very high value drug, it is prohibitively expensive and out of our reach. Being not covered by any international insurance, we will have to bear the hospitalization costs in the US on our own with the help of friends and family.
Here is a brief preliminary estimate of the expenses (in INR) going ahead for covering her treatment for six months:
Name: Prerna Katiyar
Age: 40 years
Location: New Delhi
Hospital where Cancer was diagnosed: Rajiv Gandhi Cancer Institute and Research Centre
Working at: The Economic Times
Disease: Non Small Cell Lung Cancer with EGFR, Exon-20 Insertion Mutation
Drug Required: Rybrevant / Amivantamab
Amount to be Raised: Rs. 2,04,00,000 ($ 2,55,000)
As of now there is a single targeted therapy drug called Amivantamab of Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, which has been approved by FDA for Exon-20 mutations. The approval has been granted only recently in May 2021. The trade name of the drug is now Rybrevant.
https://www.pharmaceutical-technology.com/news/fda-janssen-rybrevant/
Amivantamab can be used to treat advanced NSCLC when the cells have an exon 20
mutation. This drug is given as an infusion
into a vein (IV).
https://www.cancer.org/content/dam/CRC/PDF/Public/8706.00.pdf (Pg. 22)
It has shown promise compared to other alternative Exon-20 specific targeted therapies, all of which are currently at clinical trial stage only.
https://www.clinicaltrialsarena.com/comment/janssens-amivantamab-has-competitive-edge-over-spectrums-and-takedas-exon-20-mutation-directed-tkis-in-nsclc/
As of now, the drug is not available in India and it is also not available for import. The situation is expected to remain the same for the coming few months. Hence, presently the only way to commercially access the drug is to get it in the US.
Since the cancer cells have already spread to her right leg, we want to start her treatment right away wherever the drug is available and come back to India as soon as the drug becomes available in India.
Three vials of the drug are required to be administered every week for the first four weeks, and subsequently infusion of three vials would be required once every two weeks. This drug would be administered along with Chemotherapy.
Being a very high value drug, it is prohibitively expensive and out of our reach. Being not covered by any international insurance, we will have to bear the hospitalization costs in the US on our own with the help of friends and family.
Here is a brief preliminary estimate of the expenses (in INR) going ahead for covering her treatment for six months:
- Drug Cost - INR 1,08,00,000/- (~USD 135,000)
- Drug Administration, Chemotherapy, Hospitalization and Periodic Evaluation Charges - INR 60,00,000/- (~USD 75,000)
- US Oncologist Consultation & Evaluation - INR 20,00,000/- (~USD 25,000)
- Travel and Living Expenses - INR 16,00,000/- (~USD 20,000)
Total Estimated Cost - INR 2,04,00,000/- (USD 255,000)
We need to first arrange the funds and submit the proof to the US consulate for obtaining the Visa.
We will be bearing the expenses for her treatment options available in India on our own.
I sincerely appeal to you all to help us in this time of need and support us. Every contribution counts and we and our family are forever grateful for your help.
We need to first arrange the funds and submit the proof to the US consulate for obtaining the Visa.
We will be bearing the expenses for her treatment options available in India on our own.
I sincerely appeal to you all to help us in this time of need and support us. Every contribution counts and we and our family are forever grateful for your help.
